IP Library › Granted Patent US 9,616,226
Granted Patent B2
US 9,616,226 · App. 14/850,089 · Granted Apr 11, 2017

Devices and systems for treating obstetric and gynecological disorders

Inventors: Charles Lockwood (Bexley, OH); Edmund Funai (New Albany, OH); Ali R. Rezai (Columbus, OH)
Assignee: Ohio State Innovation Foundation
A61N1/36007A61N1/0521A61N1/0551A61N1/36071A61N1/36107A61N1/36139
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,616,226
App. No.
14/850,089
Granted
Apr 11, 2017
Kind
B2
Abstract

One aspect of the present disclosure relates to a therapy delivery device for treating an obstetric or gynecological disorder other than urinary incontinence in a subject. The therapy delivery device can include a housing, at least one electrode, and a power source. The housing can be configured for implantation in a reproductive system of the subject. The at least one electrode can be connected to the housing and be configured to delivery an electrical signal to an autonomic nervous system nerve target. The power source can be in electrical communication with the at least one electrode.

Claims (31)

1. A therapy delivery system for treating an obstetric or gynecological disorder other than urinary incontinence in a subject, the therapy delivery system comprising:

a housing configured for implantation in a reproductive system of the subject;

at least one electrode connected to the housing and configured to deliver an electrical signal to an autonomic nervous system (ANS) nerve target; and

a controller programmed to direct delivery of the electrical signal to the at least one electrode to modulate activity at the ANS nerve target site to treat the obstetric or gynecological disorder.

2. The therapy delivery system of claim 1 , wherein the housing is configured for implantation in a uterus, a vagina, an ovary, a fallopian tube, or a cervix of the subject.

3. The therapy delivery system of claim 1 , wherein the controller is programmed to delivery an electrical signal having a frequency of about 1000 Hz or greater.

4. The therapy delivery system of claim 1 , wherein the ANS nerve target is a parasympathetic nerve.

5. The therapy delivery system of claim 4 , wherein the parasympathetic nerve is a pelvic splanchnic nerve.

6. The therapy delivery system of claim 1 , wherein the ANS nerve target is a sympathetic nerve.

7. The therapy delivery system of claim 6 , wherein the sympathetic nerve is a hypogastric nerve, a hypogastric plexus, an inferior hypogastric plexus, a uterovadinal plexus, a T10-L1 sympathetic ganglion, a pudendal nerve, an efferent sympathetic fiber thereof, or an afferent sympathetic fiber thereof.

8. The therapy delivery system of claim 1 , wherein the obstetric or gynecological disorder is pre-term labor.

9. A therapy delivery system for treating an obstetric or gynecological disorder other than urinary incontinence in a subject, the therapy delivery system comprising:

a housing configured for implantation in a uterus, a vagina, an ovary, a fallopian tube, or a cervix of the subject;

at least one electrode connected to the housing and configured to deliver an electrical signal to a sympathetic nerve target; and

a controller programmed to direct delivery of the electrical signal to the at least one electrode to modulate activity at the sympathetic nerve target to treat the obstetric or gynecological disorder.

10. A method for treating an obstetric or gynecological disorder other than urinary incontinence in a subject, the method comprising the steps of:

providing a therapy delivery device, the therapy delivery device including a housing, at least one electrode connected to the housing, and a power source in electrical communication with the at least one electrode;

placing the therapy delivery device into a reproductive system of the subject so that the at least one electrode is in electrical communication with an ANS nerve target; and

activating the therapy delivery device to deliver an electrical signal to the ANS nerve target to modulate activity at the ANS nerve target to treat the obstetric or gynecological disorder.

11. The method of claim 10 , wherein said providing step further includes providing a closed-loop therapy delivery system, the system including a sensing component and a controller that are in communication with the housing, the sensing component being configured to detect at least one physiological parameter associated with the obstetric or gynecological disorder, the controller being configured to automatically coordinate operation of the power source and the sensing component.

12. The method of claim 11 , further comprising the steps of:

sensing at least one physiological parameter associated with the obstetric or gynecological disorder;

generating a sensor signal based on the at least one physiological parameter; and

activating the therapy delivery device to adjust application of the electrical signal to the ANS nerve target in response to the sensor signal to treat the obstetric or gynecological disorder.

13. The method of claim 10 , wherein the obstetric or gynecological disorder is selected from the group consisting of pre-term labor, fecal incontinence, infertility, irregular menstrual cycle, polycystic ovary syndrome, dysmenorrhea, a amenorrhea, sexual dysfunction, visceral pain syndromes, uterine pain syndromes, vulvodynia, vaginismus, pre-menstrual stress, and pre-menstrual dysphoric disorder.

14. The method of claim 10 , wherein said placing step further includes implanting the housing in a uterus, a vagina, an ovary, a fallopian tube, or a cervix of the subject.

15. The method of claim 10 , wherein the ANS nerve target is a parasympathetic nerve.

16. The method of claim 15 , wherein the parasympathetic nerve is a pelvic splanchnic nerve.

17. The method of claim 10 , wherein the ANS nerve target is a sympathetic nerve.

18. The method of claim 17 , wherein the sympathetic nerve is a hypogastric nerve, a hypocastric plexus, an inferior hypogastric piexus, a uterovaginal plexus, a T10-L1 sympathetic ganglion, a pudendal nerve, an efferent sympathetic fiber thereof, or an afferent sympathetic fiber thereof.

19. The method of claim 10 , wherein the electrical signal has a frequency of about 10,000 Hz to about 25,000 Hz.

Continuity (3)
Continuation In Part PCTUS2014022423 · Mar 10, 2014
Provisional Application 61776046 · Mar 11, 2013
Related Publication 20160045728A1 · Feb 18, 2016